



Announcement TRUVADA® (emtricitabine + tenofovir disoproxil fumarate)

Product: TRUVADA (emtricitabine + tenofovir disoproxil fumarate)

Pharmaceutical Form: Film-coated tablet

Presentations: (200 + 300) MG FILM-COATED TABLET IN HDPE PLASTIC BOTTLE X 30

(200 + 300) MG FILM-COATED TABLET IN BLISTER PACK IN HDPE PLASTIC BOTTLE X 30

Registration Numbers: 1.0929.0004.001-4 and 1.0929.0004.002-2

Gilead Sciences Farmacêutica do Brasil Ltda, registered under CNPJ 15.670.288/0001-89, hereby informs the permanent discontinuation of the importation of TRUVADA® (emtricitabine + tenofovir disoproxil fumarate), film-coated tablets, 200 mg + 300 mg, in all registered presentations, due to a commercial and strategic decision by the company.

The company understands the importance of this medication for patients, families, and healthcare professionals, and informs that there are other therapeutic alternatives available on the market, including generic and branded generic versions of TRUVADA®. Therefore, it is important that patients and physicians discuss the best course of treatment.

The Brazilian Health Regulatory Agency (ANVISA) was notified of this decision on June 18, 2024, in accordance with Regulation RDC No. 18 of April 4, 2014.